Lineage Cell Therapeutics (LCTX) Expected to Announce Earnings on Thursday

Key Points

• Lineage Cell Therapeutics is expected to report Q3 2026 results after the market closes on November 5, with analysts forecasting a loss of $0.02 per share and revenue of $2.32 million.
• In its previous quarter, the company reported a $0.03-per-share loss in line with estimates, while revenue of $1.07 million fell short of the $1.84 million consensus estimate. Analysts expect full-year and next-year losses of $0.07 and $0.04 per share, respectively.
• The stock recently traded near $1.04, well below its 12-month high of $2.09, but all four covering analysts maintain Buy ratings and an average price target of $6.25.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) is expected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.02) per share and revenue of $2.32 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.84 million. Lineage Cell Therapeutics had a negative return on equity of 73.06% and a negative net margin of 246.58%. On average, analysts expect Lineage Cell Therapeutics to post ($0.07) EPS for the current fiscal year and ($0.04) EPS for the next fiscal year.

Lineage Cell Therapeutics Trading Up 1.0%

Shares of LCTX opened at $1.04 on Thursday. The company's 50 day simple moving average is $1.02 and its 200-day simple moving average is $1.34. The firm has a market cap of $263.03 million, a PE ratio of -5.47 and a beta of 1.60. Lineage Cell Therapeutics has a 12-month low of $0.88 and a 12-month high of $2.09.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating on shares of Lineage Cell Therapeutics in a research note on Tuesday, July 14th. Four analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $6.25.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc is a biotechnology company focused on developing allogeneic cell therapies for unmet medical needs. The company uses its proprietary cell differentiation and manufacturing technologies to create specialized human cells intended to replace, repair or support damaged tissues.

Lineage's lead program, OpRegen, is an investigational retinal pigment epithelium cell replacement therapy being developed for geographic atrophy, an advanced form of dry age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.